Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHI-902 for Social Anxiety Disorder
NCT04086342Phase 2Withdrawn
- Sponsor
- C³ Cannabinoid Compound Company
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHI-902 in Social Anxiety Disorder (SAD), sponsored by C³ Cannabinoid Compound Company. Planned start Jan 2020; status: withdrawn.
02
Drugs
CHI-902
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT04086342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086342.